Composition, application of composition in external preparation for skin and external preparation for skin

Abstract

The invention provides a composition capable of promoting collagen synthesis and application of the composition in preparation of a skin external preparation with an anti-aging effect. The composition comprises artemisia apiacea oil serving as an effective component and phytol serving as an auxiliary synergistic component. The composition not only has the effect of efficiently promoting collagen synthesis, but also has the advantages of mildness, safety, no irritation and low cost. The invention also provides an external preparation for skin, which comprises the composition, and the external preparation for skin is selected from face cream, emulsion, gel, toning lotion, essence, mask, eye cream, aerosol cleaning foam, shower gel or facial cleanser.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, and in particular to a composition that promotes collagen synthesis, the application of the composition in the preparation of a topical skin agent with anti-aging effects, and a topical skin agent. Background Technology

[0002] Skin aging is a complex physiological process characterized by a decrease in the synthesis and an increase in the degradation of type I collagen in the dermis. The loss of this type of collagen leads to typical signs of aging such as wrinkles, sagging, and loss of elasticity. Therefore, activating dermal fibroblasts to synthesize type I collagen has become an important approach to preventing and improving skin aging.

[0003] Currently, there are many active ingredients that can be used to promote collagen production, mainly including vitamin A and its derivatives (retinols), vitamin C and its derivatives, and peptides (such as palmitoyl tripeptide-5). However, these ingredients generally have limitations such as limited applicable populations and poor skin tolerance, making it difficult to meet the needs of widespread use. Specifically, vitamin A and its derivatives (retinols) and vitamin C and its derivatives can directly upregulate the expression of collagen-related genes by binding to relevant receptors in the cell nucleus, showing clear anti-aging effects, but they generally have limitations such as strong irritation, poor photostability, and the need for caution in pregnant women. Peptide ingredients such as palmitoyl pentapeptide-4 and acetyl hexapeptide-8 can indirectly promote collagen synthesis or improve dynamic wrinkles by mimicking extracellular matrix signals or inhibiting neurotransmitter release, but these ingredients generally have large molecular weights, inconsistent transdermal absorption efficiency, and high raw material costs.

[0004] Plant-derived active ingredients have garnered significant attention from the industry and market due to their gentle effects, low irritation, high safety profile, and good consumer acceptance. However, the anti-aging effects of conventional plant-derived active ingredients are generally weak, failing to achieve the desired anti-aging and collagen synthesis-promoting effects. Therefore, developing products that combine highly effective collagen-promoting and anti-aging effects with gentle, safe, and non-irritating properties at a low cost is a core technological challenge that urgently needs to be overcome in this field. Summary of the Invention

[0005] The present invention provides the following technical solutions to solve the above-mentioned technical problems.

[0006] The present invention provides a composition that promotes collagen synthesis, the composition comprising the active ingredient artemisinin oil and the auxiliary synergist phytol.

[0007] The composition provided by this invention not only has the effect of effectively promoting collagen synthesis, but also has the advantages of being mild, safe, non-irritating, and low-cost.

[0008] Optionally, the composition comprises the following components in weight percentages: 0.05%-0.3% artemisia annua oil and 0.1%-1.0% phytol.

[0009] Optionally, the ratio of artemisia oil to phytol is 0.2:1 to 0.9:1.

[0010] Optionally, the ratio of artemisia oil to phytol is 0.6:1 to 0.8:1.

[0011] Optionally, the composition promotes the biosynthesis of collagen in human skin cells, thereby increasing skin elasticity.

[0012] Optionally, both the phytol and the artemisia oil are derived from plant extracts or chemical synthesis.

[0013] The application of the above-described composition in the preparation of topical skin agents with anti-aging effects.

[0014] The composition provided by this invention not only has the effect of effectively promoting collagen synthesis, but also has the advantages of being mild, safe, non-irritating, and low-cost. When applied to topical skin agents, it can achieve excellent anti-aging effects.

[0015] The present invention also provides a topical skin agent comprising the composition described in the above embodiments, wherein the topical skin agent is selected from: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, shower gel, or facial cleanser.

[0016] Using the above technical solution, the resulting topical skin agent can effectively promote collagen synthesis, thereby achieving anti-aging and skin care effects.

[0017] Optionally, the topical skin agent is selected from serums, which include the following components in weight percentages: artemisia annua oil 0.05%-0.3%, phytol 0.1%-1.0%, moisturizer 3.5%-10%, and emollient 5%-13%.

[0018] Optionally, the topical skin agent is selected from face creams or lotions, which include the following components in weight percentage: 0.05%-0.3% artemisia annua oil, 0.1%-1.0% phytol, 3.5%-10% moisturizer, 5%-13% emollient, and 1.5%-5% emulsifier. Attached Figure Description

[0019] Figure 1 A bar chart showing the effect of different cell treatments on type I collagen expression in fibroblasts. Detailed Implementation

[0020] The following specific embodiments illustrate the implementation of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. Although the description of the present invention is presented in conjunction with preferred embodiments, this does not mean that the features of the invention are limited to these embodiments. On the contrary, the purpose of describing the invention in conjunction with embodiments is to cover other options or modifications that may be derived based on the claims of the present invention. To provide a deep understanding of the invention, many specific details will be included in the following description. The invention may also be implemented without using these details. Furthermore, to avoid confusion or obscuring the focus of the invention, some specific details will be omitted in the description. It should be noted that, unless otherwise specified, the embodiments and features in the embodiments of the present invention can be combined with each other.

[0021] It should be noted that in this specification, similar reference numerals and letters in the following figures indicate similar items. Therefore, once an item is defined in one figure, it does not need to be further defined and explained in subsequent figures.

[0022] The terms “first”, “second”, etc., are used only to distinguish descriptions and should not be interpreted as indicating or implying relative importance.

[0023] To make the objectives, technical solutions, and advantages of the present invention clearer, the embodiments of the present invention will be described in further detail below with reference to the accompanying drawings.

[0024] This invention provides a composition comprising artemisia annua oil and phytol. Specifically, this invention provides a composition that promotes collagen synthesis, comprising artemisia annua oil and phytol. More specifically, this invention provides a composition that promotes collagen synthesis, comprising the active ingredient artemisia annua oil and the synergistic ingredient phytol.

[0025] Studies have shown that in the composition of this invention, artemisia annua oil, as the core active ingredient, can directly promote the synthesis of collagen, especially type I collagen, while phytol, as an auxiliary synergist, can further enhance the efficacy based on the effects of artemisia annua oil. Compared with the single-ingredient application, the combined use of the two can significantly improve the level of collagen synthesis. After in-depth research into the underlying mechanism of action, the inventors concluded that the active ingredients in artemisia annua oil can activate specific receptors such as growth factor receptors on the skin fibroblast membrane, initiate downstream collagen synthesis signaling pathways such as TGF-β / Smad, and complete the initial activation of intracellular signals. Phytol, as a lipophilic molecule, can embed into the phospholipid bilayer of the fibroblast membrane to stabilize the membrane structure and reduce the loss of signal molecules in transverse membrane transmission. At the same time, it can activate phosphatidylinositol kinase (PIK) and promote the synthesis of the membrane phospholipid component phosphatidylinositol-4,5-bisphosphate (PIP2), providing sufficient substrate for subsequent signal transduction. When used in combination, the two can produce a synergistic effect. Specifically, the signal transduction triggered by the activation of receptors by artemisinin oil can promote the hydrolysis of PIP2 to generate the second messenger inositol triphosphate (IP3) and diglyceride (DAG). The pre-accumulated PIP2 substrates of phytol can significantly increase the production of the second messenger, thereby enhancing the intensity of intracellular signal transduction. Among them, IP3 mediates the release of intracellular calcium ions, and DAG activates protein kinase C (PKC). The amplified signals together accelerate the activation of downstream transcription factors, ultimately driving the transcription and translation of type I collagen-related genes efficiently and increasing the level of collagen synthesis.

[0026] The composition provided by this invention not only has the effect of effectively promoting collagen synthesis, but also has the advantages of being mild, safe, non-irritating, and low-cost.

[0027] Furthermore, in the above embodiments, the composition provided by the present invention comprises an active ingredient and an inactive ingredient. The active ingredient consists of artemisinin oil and phytol, and its main function is to promote the synthesis of type I collagen. The inactive ingredient can be a commonly used excipient in topical skin preparations, serving only auxiliary functions such as formulation shaping, stabilization, and moisturizing, and does not possess collagen-promoting activity.

[0028] Furthermore, in the above embodiments, the composition comprises the following components in weight percentages: 0.05%-0.3% artemisinin oil and 0.1%-1.0% phytol. Studies have shown that combining artemisinin oil and phytol within the above content range can significantly improve collagen synthesis efficiency. Simultaneously, the composition provided by this invention achieves excellent efficacy with only a low amount of active ingredient, reducing raw material and production costs, and minimizing irritation when the finished product is applied to the skin, thus combining efficacy, economy, and safety.

[0029] Further, in the above embodiments, the ratio of artemisia annua oil to phytol is 0.2:1 to 0.8:1. Studies have found that controlling the proportion of artemisia annua oil within the above range enables the composition to achieve excellent collagen synthesis-promoting effects. Preferably, the ratio of artemisia annua oil to phytol is 0.6:1 to 0.8:1. More preferably, the ratio of artemisia annua oil to phytol is 0.8:1. Even more preferably, the mass ratio of artemisia annua oil to phytol is 0.8:1. This ratio is the optimal ratio obtained by the inventors through extensive experimental screening. Under this ratio, the composition exhibits the best collagen synthesis-promoting effect, and the synergistic effect of artemisia annua oil and phytol is fully utilized.

[0030] Artemisia annua oil is a volatile essential oil extracted from the plant Artemisia annua, belonging to the Asteraceae family. Current research largely focuses on its antibacterial, antimalarial, and anti-inflammatory pharmacological activities, and its applications and understanding are limited to this scope. Phytol, a terpene compound widely distributed in the plant kingdom and a key component of chlorophyll, is commonly used in cosmetic formulations as a moisturizer, emulsifier, and skin conditioning agent. Experimental results show that neither of these compounds, when used alone, significantly promotes collagen production. The inventors unexpectedly discovered that combining artemisia annua oil and phytol synergistically and significantly enhances collagen synthesis efficiency. The compositions in the above embodiments of this invention can effectively promote the biosynthesis of collagen in human skin cells, thereby increasing skin elasticity and achieving anti-aging effects.

[0031] Furthermore, in the above embodiments, both artemisia oil and phytol can be extracted from plants or prepared through chemical synthesis. Preferably, both artemisia oil and phytol are derived from plant extracts. Specifically, artemisia oil can be extracted from artemisia using processes such as steam distillation and supercritical CO2 extraction. Phytol can be extracted from various plants such as alfalfa, tea, and wheat germ.

[0032] The present invention also discloses the use of the compositions provided in the above embodiments in the preparation of topical skin agents with anti-aging effects.

[0033] The composition provided by this invention not only has the effect of effectively promoting collagen synthesis, but also has the advantages of being mild, safe, non-irritating, and low-cost. When applied to topical skin agents, it can achieve significant anti-aging effects.

[0034] Furthermore, in the above embodiments, the topical skin agent is selected from: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, shower gel, or facial cleanser.

[0035] Furthermore, in the above embodiments, the topical skin agent is selected from an essence, which includes the following components in weight percentage: artemisia annua oil 0.05% - 0.3%, phytol 0.1% - 1.0%, moisturizer 3.5% - 10%, and emollient 5% - 13%.

[0036] Furthermore, in the above embodiments, the topical skin agent is selected from face cream or lotion, and the face cream or lotion includes the following components in weight percentage: artemisia annua oil 0.05%-0.3%, phytol 0.1%-1.0%, moisturizer 3.5%-10%, emollient 5%-13%, and emulsifier 1.5%-5%.

[0037] The present invention also provides a topical skin agent comprising the composition in any of the above embodiments, wherein the topical skin agent is selected from: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, shower gel, or facial cleanser.

[0038] Furthermore, in the above embodiments, the topical skin agent is selected from an essence, which includes the following components in weight percentage: artemisia annua oil 0.05% - 0.3%, phytol 0.1% - 1.0%, moisturizer 3.5% - 10%, and emollient 5% - 13%. Among them, the moisturizer can be glycerin or panthenol.

[0039] Further, in the above embodiments, the topical skin agent is selected from face creams or lotions, wherein the face cream or lotion comprises the following components in weight percentages: artemisia annua oil 0.05%-0.3%, phytol 0.1%-1.0%, moisturizer 3.5%-10%, emollient 5%-13%, and emulsifier 1.5%-5%. The emollient can be squalane or caprylic / capric triglyceride. The emulsifier can be cetearyl alcohol olive oil ester or PEG-100 stearate.

[0040] Furthermore, in the above embodiments, the essence comprises the following components in weight percentage: 0.05%~0.3% artemisia annua oil, 0.1%~1.0% phytol, 3%~8% glycerin (moisturizer), 0.5%~2% panthenol (moisturizer), 2%~5% squalane (emollient), 3%~8% caprylic / capric triglyceride (emollient), 0.1%~0.3% carbomer (thickener), 0.1%~0.3% triethanolamine (neutralizer), 0.5%~1.0% phenoxyethanol and ethylhexylglycerin (mass ratio 1:1) (preservative), 0.1%~0.5% tocopheryl acetate (antioxidant), and the remainder is deionized water.

[0041] Further, in the above embodiments, the face cream or lotion includes the following components in weight percentage: 0.05%~0.3% artemisia annua oil, 0.1%~1.0% phytol, 3%~8% glycerin (moisturizer), 0.5%~2% panthenol (moisturizer), 2%~5% squalane (emollient), 3%~8% caprylic / capric triglyceride (emollient), 0.1%~0.3% carbomer (thickener), 0.1%~0.3% triethanolamine (neutralizer), 0.5%~1.0% phenoxyethanol and ethylhexylglycerin (mass ratio 1:1) (preservative), 0.1%~0.5% tocopheryl acetate (antioxidant), 1%~3% cetearyl alcohol olive oil ester (emulsifier), 0.5%~2% PEG-100 stearate (emulsifier); the remaining component is deionized water.

[0042] Studies have shown that the serums, creams, and lotions provided by this invention, due to their formulation of highly effective anti-aging active ingredients, exhibit significant wrinkle-reducing effects after 4 and 8 weeks of continuous use, and further enhanced anti-aging efficacy with continued use. Simultaneously, these products are gentle, safe, and non-irritating to the skin, effectively broadening their target audience and usage scenarios. Furthermore, their low raw material costs facilitate industrialization and promotion, giving them a significant competitive advantage in the market.

[0043] The technical solution of the present invention will be further described below with reference to embodiments and comparative examples.

[0044] Blank control group

[0045] Cell seeding: Human skin fibroblasts (HFF-1) in logarithmic growth phase were selected and cultured in DMEM medium (Dubai modified Eagle medium) containing 10% fetal bovine serum (FBS). When the cells reached approximately 80% confluence, they were digested with 0.05% trypsin-EDTA solution and centrifuged at 1000 rpm for 5 min to collect the cells. After centrifugation, the cells were resuspended in DMEM medium containing 10% FBS and counted using a hemocytometer. Subsequently, cells were seeded at 1.8 × 10⁻⁶ cells / mL. 4 Cells were seeded at a density per well into 24-well cell culture plates pre-filled with cell spreaders and cultured in a constant temperature incubator at 37 ℃ and 5% CO2 to ensure normal cell adhesion and growth.

[0046] Cell treatment: 24 hours after cell seeding, discard the original culture medium in each well of the culture plate, add DMEM medium containing 10% fetal bovine serum (FBS), and incubate for another 48 hours in a constant temperature incubator at 37 ℃ and 5% CO2.

[0047] Positive control group

[0048] Similar to the blank control group, the only difference was that the DMEM medium contained 20 ng / mL of TGF-β1 (transforming growth factor β1).

[0049] Comparative Example 1

[0050] Cell seeding: Human skin fibroblasts (HFF-1) in logarithmic growth phase were selected and cultured in DMEM medium (Dubai modified Eagle medium) containing 10% fetal bovine serum (FBS). When the cells reached approximately 80% confluence, they were digested with 0.05% trypsin-EDTA solution and centrifuged at 1000 rpm for 5 min to collect the cells. After centrifugation, the cells were resuspended in DMEM medium containing 10% FBS and counted using a hemocytometer. Subsequently, cells were seeded at 1.8 × 10⁻⁶ cells / mL. 4 Cells were seeded at a density per well into 24-well cell culture plates pre-filled with cell spreaders and cultured in a constant temperature incubator at 37 ℃ and 5% CO2 to ensure normal cell adhesion and growth.

[0051] Cell treatment: Phytol was dissolved in DMSO (dimethyl sulfoxide) to prepare a 0.625% phytol stock solution, which was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a 0.0625% phytol working solution. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-mentioned 0.0625% phytol working solution was added. The plate was then incubated at 37 ℃ and 5% CO2 for another 48 hours.

[0052] Comparative Example 2

[0053] Similar to Comparative Example 1, the only difference was that the cell treatment steps were as follows: Artemisia annua oil was dissolved in DMSO (dimethyl sulfoxide) to prepare a 0.5% (w / w) Artemisia annua oil stock solution, which was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a 0.05% (w / w) Artemisia annua oil working solution. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-mentioned 0.05% (w / w) Artemisia annua oil solution was added. The plate was then incubated at 37 ℃ and 5% CO2 for another 48 hours.

[0054] Comparative Example 3

[0055] Similar to Comparative Example 1, the only difference was the cell treatment steps: Artemisia annua oil and phytosterols were dissolved together in dimethyl sulfoxide (DMSO) to prepare a mixed stock solution containing 0.5% Artemisia annua oil and 0.625% phytosterols. This stock solution was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a working solution containing 0.05% Artemisia annua oil and 0.0625% phytosterols. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-prepared working solution was added. The plate was then incubated at 37 ℃ and 5% CO2 for another 48 hours.

[0056] Comparative Example 4

[0057] Similar to Comparative Example 1, the only difference was the cell treatment steps: phytol and the antioxidant plant oil jojoba (Simondia chinensis) seed oil were dissolved together in dimethyl sulfoxide (DMSO) to prepare a mixed stock solution containing 0.625% phytol and 0.5% jojoba seed oil. This stock solution was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a working solution containing 0.0625% phytol and 0.05% jojoba seed oil. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-prepared working solution was added. The plate was then incubated at 37°C with 5% CO2 for another 48 hours.

[0058] Comparative Example 5

[0059] Similar to Comparative Example 2, the only difference is that the mass concentration of the artemisia annua oil working solution prepared in the cell treatment step is 0.20%.

[0060] Comparative Example 6

[0061] Similar to Comparative Example 1, the only difference was the cell treatment steps: retinol was dissolved in DMSO to prepare a 1% retinol stock solution, which was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a 0.1% retinol working solution. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-mentioned 0.1% retinol working solution was added. The plate was then incubated at 37 ℃ and 5% CO2 for another 48 hours.

[0062] Comparative Example 7

[0063] Similar to Comparative Example 1, the only difference was that the cell treatment steps were as follows: Acetyl hexapeptide-8 was dissolved in sterile water to prepare a 0.01% (w / w) acetyl hexapeptide-8 stock solution, which was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a 0.001% (w / w) acetyl hexapeptide-8 working solution. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-mentioned 0.001% (w / w) acetyl hexapeptide-8 working solution was added. The plate was then incubated at 37°C and 5% CO2 for another 48 hours.

[0064] Example 1

[0065] Similar to Comparative Example 3, the only difference was the processing steps: Artemisia annua oil and phytol were dissolved together in DMSO to prepare a mixed stock solution containing 0.5% Artemisia annua oil and 0.625% phytol. This stock solution was then diluted with DMEM medium containing 10% fetal bovine serum (FBS) to obtain a working solution containing 0.05% Artemisia annua oil and 0.0625% phytol. Twenty-four hours after cell seeding, the original culture medium in each well of the culture plate was discarded, and the above-prepared working solution was added. The plate was then incubated at 37 ℃ and 5% CO2 for another 48 hours.

[0066] The following procedures were performed on the above-mentioned blank control group, comparative examples, and implementation examples:

[0067] After incubation, the cells in each well were fixed and subjected to subsequent immunofluorescence staining. The specific steps were as follows: the original culture medium in each well was aspirated, ice-cold methanol was added to each well, and the cells were fixed for 15 minutes; after fixation, the cells were gently washed once with 1×DPBS buffer, and the washing solution was aspirated; then blocking solution was added to each well, and the cells were blocked for 1 hour; after blocking, type I collagen (COL I) specific primary antibody was added, and the cells were incubated overnight; after primary antibody incubation, the cells were washed three times with 1×DPBS buffer, and the washing solution was aspirated; then Alexa Fluor 488-labeled anti-rabbit secondary antibody was added, and the cells were incubated for another 1.5 hours; after secondary antibody incubation, the cells were washed three times again with 1×DPBS buffer, the washing solution was aspirated, and the cell slides were transferred to glass slides containing DAPI mounting medium.

[0068] After the above treatment, the cells in each well were observed and fluorescent photographs were taken using a fluorescence microscope. Subsequently, image analysis software was used to quantitatively calculate the fluorescence intensity of all the photographs. Simultaneously, the relative expression level of COL1A1 mRNA and the amount of collagen secreted by cells in the blank control group, Comparative Example 6, Comparative Example 7, and Example 1 were measured. The results are recorded in Table 1. It should be noted that COL1A1 is a key functional gene encoding type I collagen, and its relative mRNA expression level directly reflects the transcriptional activity of collagen synthesis-related genes within the cell. The higher the value, the stronger the cell's ability to synthesize collagen. The blank control group consisted of cells cultured in basal culture medium without any added exogenous collagen-promoting active ingredients; its results represent the expression level of type I collagen genes and the level of protein secretion in skin fibroblasts under basic physiological conditions and can be used as a blank reference for this experiment. In addition, the relative expression level of type I collagen (COL I) in cells from the blank control group, comparative examples 1 to 5, and Example 1 was simultaneously measured, i.e., the relative fluorescence intensity of type I collagen (COL I). The relative fluorescence intensity of type I collagen (COL I) was calculated as: fluorescence intensity of each experimental group / fluorescence intensity of the blank control group. The fluorescence intensity of the blank control group (BC) was set as 100% for normalization. This value directly reflects the expression level of type I collagen in cells; a higher fluorescence intensity indicates a greater expression level of type I collagen in the cells. The experiment was conducted in triplicate, and SEM (standard error) was used for the error bars. The results were compared significantly with the blank control group and Example 1. All detection results are recorded in Table 2.

[0069] Table 1

[0070]

[0071] Note: t-tests were used for statistical analysis of data between groups. * indicates that the difference was statistically significant compared with the blank control group (P<0.05), and ** indicates that the difference was extremely statistically significant compared with the blank control group (P<0.01).

[0072] Table 1 shows that when artemisia annua oil and phytol are used in combination as active ingredients, the results are superior to those of commonly available retinol and peptide ingredients (such as acetyl hexapeptide-8) in terms of both relative expression level of COL1A1 mRNA and collagen secretion. Specifically, both indicators in Example 1 showed highly significant differences compared to the blank control group (P<0.01). Overall, the experimental results indicate that the relevant groups of this invention are significantly superior to commercially available retinol and acetyl hexapeptide-8 in promoting both type I collagen gene transcription and protein secretion.

[0073] Table 2

[0074]

[0075] Note: t-tests were used for statistical analysis of data between groups. * indicates a statistically significant difference compared with the blank control group (P<0.05), ** indicates an extremely statistically significant difference compared with the blank control group (P<0.01), *** indicates an extremely statistically significant difference compared with the blank control group (P<0.001), and ns indicates no statistically significant difference compared with the blank control group (P>0.05).

[0076] Table 2 shows that compared with the groups using phytol alone, artemisia oil alone, and the groups using a combination of artemisia oil and phytosterol, and the groups using a combination of antioxidant plant oil and phytol, the collagen-promoting effects of the above groups were all inferior to the group using a combination of artemisia oil and phytol in this invention. Further research revealed that when using a combination of artemisia oil and phytol, only a low concentration, such as 0.005% artemisia oil and 0.0625% phytol, was required to achieve a better collagen-promoting effect than the group using 0.2% artemisia oil alone. Therefore, the method of using a combination of artemisia oil and phytol in this invention can achieve excellent collagen-promoting effects with only a low concentration, effectively reducing experimental and application costs and possessing the significant advantage of being mild and non-irritating.

[0077] Furthermore, to more intuitively demonstrate the collagen-promoting effects of Comparative Example 1, Comparative Example 2, and Example 1, this invention also provides Figure 1 below. As shown in Figure 1, the effect level of Comparative Example 2 compared to Comparative Example 1 and Example 1 is ++; the effect levels of Example 1 compared to Comparative Example 1 and Comparative Example 2 are marked as +++ and ++, respectively, indicating that the effect of the culture medium in Example 1 on promoting type I collagen expression is significantly better than that in Comparative Example 1 and Comparative Example 2, demonstrating a superior collagen-promoting effect. These results fully confirm that the combined use of phytol and artemisia annua oil can produce a synergistic effect on the expression of type I collagen in fibroblasts.

[0078] The following preparation of the serum uses the composition of Example 1. The serum comprises the following components in weight percentage:

[0079] • Artemisia annua oil: 0.05%

[0080] Phytosterol: 0.0625%

[0081] • Glycerin: 5.0%

[0082] • Sodium hyaluronate: 0.1%

[0083] • 1,3-Butanediol: 3.0%

[0084] • Carbomer: 0.2%

[0085] • Triethanolamine: 0.15%

[0086] • p-Hydroxyacetophenone: 0.5%

[0087] • Deionized water: Add to 100%

[0088] After preparation, 40 healthy female volunteers aged 35-50 were recruited. All volunteers had mild to moderate crow's feet on their faces and had no skin diseases, allergies, or other conditions that might affect the experimental results.

[0089] Next, the volunteers were randomly divided into two groups of 20 each: an experimental group and a control group. The experimental group used the essence prepared according to this invention, while the control group used an essence without the aforementioned artemisinin oil and phytol active ingredients. All other components and their concentrations were identical to those in the experimental group, with any missing volume made up with deionized water. Both groups of volunteers used the corresponding product twice daily, morning and evening, for eight consecutive weeks, following a standardized procedure. During this period, they avoided using other products with anti-wrinkle or skincare effects to ensure consistent experimental conditions.

[0090] The testing time points are set at three points: before use (Day 0), after 4 weeks of continuous use (Day 28), and after 8 weeks of continuous use (Day 56). The testing indicators and methods are as follows:

[0091] Quantitative detection of crow's feet: Using a skin image analysis system (such as VISIA-CR), the crow's feet area of ​​volunteers is photographed and analyzed to accurately quantify the average depth and total volume of crow's feet, thereby evaluating the product's effect on improving crow's feet;

[0092] Skin elasticity testing: Using a Cutometer® skin elasticity meter, the skin elasticity parameter R2 was measured in the same fixed area around the corner of the volunteer's eyes (a higher R2 value indicates better skin elasticity) to assess the product's effect on improving skin elasticity. After the test, the average value was calculated and recorded in Table 2 below. The data in the table are statistically analyzed with the baseline of before use (Day 0) as 0. Negative values ​​represent a decrease in the corresponding measured indicator value, and positive values ​​represent an increase in the corresponding measured indicator value. For example, "-9.5%" means that after 4 weeks of use, the average depth of wrinkles around the eyes decreased by 9.5% compared to the baseline; "+12.8%" means that after 4 weeks of use, the skin elasticity parameter R2 increased by 12.8% compared to the baseline.

[0093] Table 3

[0094] Note: * corresponds to P<0.05: statistically significant difference; ** corresponds to P<0.01: statistically significant difference.

[0095] As shown in Table 3, after 4-8 weeks of use of the serum described in this invention, facial wrinkles were significantly reduced and skin elasticity was significantly improved. Combined with the subjects' self-assessment results, after 8 weeks of use, 88% of the subjects reported a significant reduction in fine lines and wrinkles, and 92% reported improved skin firmness; moreover, no adverse reactions such as skin stinging or redness occurred during the entire trial period.

[0096] The above results demonstrate that the composition provided by this invention, when prepared as a topical skin formulation, can achieve a significant anti-wrinkle effect even with low-concentration compounding. Simultaneously, it also possesses the advantages of being mild, safe, non-irritating, and suitable for a wider range of people.

[0097] While the present invention has been illustrated and described with reference to certain preferred embodiments, those skilled in the art should understand that the above description is a further detailed explanation of the invention in conjunction with specific embodiments, and should not be construed as limiting the specific implementation of the invention to these descriptions. Various changes in form and detail can be made by those skilled in the art, including several simple deductions or substitutions, without departing from the spirit and scope of the invention.

Claims

1. A composition that promotes collagen synthesis, characterized in that, The composition includes the active ingredient artemisia oil and the auxiliary synergist phytol.

2. The composition according to claim 1, characterized in that, The composition comprises the following components in weight percentages: 0.05%-0.3% artemisia annua oil and 0.1%-1.0% phytol.

3. The composition according to claim 2, characterized in that, The mass ratio of artemisia oil to phytol is 0.2:1 to 0.9:

1.

4. The composition according to claim 3, characterized in that, The mass ratio of artemisia oil to phytol is 0.6:1 to 0.8:

1.

5. The composition according to claim 1, characterized in that, The composition promotes the biosynthesis of collagen in human skin cells, thereby increasing skin elasticity.

6. The composition according to claim 1, characterized in that, The phytol and the artemisia oil are derived from plant extracts or chemical synthesis.

7. Use of the composition according to any one of claims 1-6 in the preparation of a topical skin agent with anti-aging effects.

8. A topical skin agent, characterized in that, The composition comprising any one of claims 1-6, wherein the topical skin agent is selected from: face cream, lotion, gel, toner, serum, face mask, eye cream, aerosol cleansing foam, shower gel, or facial cleanser.

9. The topical skin agent according to claim 8, characterized in that, The topical skin agent is selected from serums, which include the following components in weight percentage: artemisia annua oil 0.05% - 0.3%, phytol 0.1% - 1.0%, moisturizer 3.5% - 10%, and emollient 5% - 13%.

10. The topical skin agent according to claim 8, characterized in that, The topical skin agent is selected from face creams or lotions, which include the following components in weight percentages: artemisia annua oil 0.05%-0.3%, phytol 0.1%-1.0%, moisturizer 3.5%-10%, emollient 5%-13%, and emulsifier 1.5%-5%.

Images